Clincosm LogoSign in Get a demo

Hepatocellular Carcinoma

Showing NaN - NaN of 176
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sequential Regorafenib Plus ICIs After HAIC for Advanced

Recruiting
  • Hepatocellular Carcinoma
  • Regorafenib combine with ICIs
  • Guangzhou, Guangdong, China
  • +1 more
Oct 15, 2022

Hepatocellular Carcinoma Trial in Guangzhou (camrelizumab& apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • camrelizumab& apatinib
  • Guangzhou, Guangzhou, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sep 18, 2022

TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone

Completed
  • Hepatocellular Carcinoma
  • TACE-HAIC
  • +3 more
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 8, 2022

Hepatocellular Carcinoma Trial in Worldwide (Durvalumab, Bevacizumab, Placebo)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Birmingham, Alabama
  • +213 more
Aug 19, 2022

Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma Trial in Guangzhou (DPMAS+LPE, PE, Comprehensive internal

Not yet recruiting
  • Immune-Mediated Hepatitis
  • +2 more
  • DPMAS+LPE
  • +2 more
  • Guangzhou, Guangdong, China
    Third Affiliated Hospital of Sun Yat-sen University
Jul 30, 2022

Liver Transplantation, Hepatocellular Carcinoma Trial in Guangzhou (FOLFOX-HAIC, Lenvatinib, PD-1 inhibitor)

Not yet recruiting
  • Liver Transplantation
  • Hepatocellular Carcinoma
  • FOLFOX-HAIC
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 26, 2022

Hepatocellular Carcinoma Trial in Foshan, Guangzhou (HAIC, FOLFOX 2d, FOLFOX 1d)

Recruiting
  • Hepatocellular Carcinoma
  • HAIC
  • +2 more
  • Foshan, Guangdong, China
  • +2 more
Jul 26, 2022

Hepatocellular Carcinoma Trial in China, Japan (Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Beijing City, China
  • +39 more
Jul 25, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Liver Resection)

Recruiting
  • Hepatocellular Carcinoma
  • Liver Resection
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jul 21, 2022

Hepatocellular Carcinoma Trial in Worldwide (Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Birmingham, Alabama
  • +132 more
Jul 20, 2022

Lenvatinib Combined Anti-PD1 Antibody for Advanced

Completed
  • Hepatocellular Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Second Affiliated Hospital of Guangzhou Medical University
Jul 8, 2022

Solid Tumors, NSCLC, Renal Cell Carcinoma Trial in China (Lenvatinib + Envafolimab, Sunitinib)

Recruiting
  • Solid Tumors
  • +3 more
  • Benbu, Anhui, China
  • +22 more
Jun 28, 2022

Hepatocellular Carcinoma Trial in Guangzhou (TCR-T, No intervention and TCR-T (at crossover))

Completed
  • Hepatocellular Carcinoma
  • TCR-T
  • No intervention and TCR-T (at crossover)
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital, Sun-Yat Sen University
Jun 27, 2022

Therapeutic Effects and Clinical Prognosis After HAIC for

Recruiting
  • Hepatocellular Carcinoma
  • Search of factors predicting therapeutic effects and prognosis
  • Guangzhou, Guangdong, China
    Department of Minimally Invasive and Interventional Radiology, L
Jun 7, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Raltitrexed, oxaliplatin (SALOX) treatment, Oxaliplatin, fluorouracil/leucovorin

Recruiting
  • Hepatocellular Carcinoma
  • Raltitrexed, oxaliplatin (SALOX) treatment
  • Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
  • Guangzhou, Guangdong, China
    Department of Minimally Invasive and Interventional Radiology, L
May 17, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Hepatic artery infusion chemo(HAIC), Durvalumab)

Recruiting
  • Hepatocellular Carcinoma
  • Hepatic artery infusion chemotherapy（HAIC）
  • Durvalumab
  • Guangzhou, Guangdong, China
    Department of Minimally Invasive and Interventional Radiology, L
May 18, 2022

Hepatocellular Carcinoma Trial in Guangzhou (TACE(Transcatheter arterial chemoembolization), Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • TACE(Transcatheter arterial chemoembolization)
  • Lenvatinib
  • Guangzhou, Guangdong, China
    Department of Minimally Invasive and Interventional Radiology, L
May 17, 2022

Hepatocellular Carcinoma Trial in Guangzhou (PD-1 mAb, Radiofequencey or microwave ablation)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1 monoclonal antibody
  • Radiofequencey or microwave ablation
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 4, 2022

Hepatocellular Carcinoma Trial in China (microwave ablation)

Recruiting
  • Hepatocellular Carcinoma
  • microwave ablation
  • Beijing, Beijing, China
  • +12 more
May 4, 2022

Hepatocellular Carcinoma Trial in Worldwide (Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2))

Recruiting
  • Hepatocellular Carcinoma
  • Los Angeles, California
  • +173 more
Mar 25, 2022

Hepatocellular Carcinoma, Portal Vein Occlusion, Tumor Thrombus Trial in Guangzhou (TACE combined with iodine-125 seeds

Active, not recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • TACE combined with iodine-125 seeds implantation
  • TACE
  • Guangzhou, Guangdong, China
    The 2nd Affiliated Hospital of Guangzhou Medical University
Mar 2, 2022

Hepatocellular Carcinoma Trial in China (CAR-GPC3 T Cells)

Completed
  • Hepatocellular Carcinoma
  • CAR-GPC3 T Cells
  • Guangzhou, Guangdong, China
  • +5 more
Feb 8, 2022

Hepatocellular Carcinoma Trial in Guangzhou (TACE/HAIC, Lenvatinib, Sintilimab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • TACE/HAIC
  • +3 more
  • Guangzhou, Guangdong, China
    Third Affiliated Hospital, Sun Yat-Sen University
Feb 15, 2022

Hepatocellular Carcinoma Trial in Guangzhou (FOLFOX-HAIC, Camrelizumab, Apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • FOLFOX-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Jan 19, 2022

HBV Reactivation Between High HBV-DNA and Low HBV-DNA Loads

Recruiting
  • Hepatocellular Carcinoma
  • ICI
  • Antiviral Prophylaxis
  • Guangzhou, Guangdong, China
  • +3 more
Jan 4, 2022